Patents by Inventor Yaffa Beck

Yaffa Beck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100204205
    Abstract: A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having histamine H1 receptor agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having histamine H1 receptor agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having histamine H1 receptor agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having histamine H1 receptor agonist activity. Methods of treatment and kits for administration are also provided.
    Type: Application
    Filed: November 2, 2009
    Publication date: August 12, 2010
    Inventors: Nir Barak, Yaffa Beck, Srinivas Rao, Jay D. Kranzler, Jeffery J. Anderson
  • Patent number: 6610520
    Abstract: A double-stranded cDNA molecule which includes DNA encoding human manganese superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA molecule which encodes human manganese superoxide dismutase has been discovered. Such molecules may be introduced in procaryotic, e.g., bacterial, or eukaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human manganese superoxide dismutase or analogs thereof which may then be recovered. By this invention, human MnSOD gene fragments from various plasmids may be ligated to yield a complete genomic human MnSOD gene fragment. Human MnSOD or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs, or treat inflammations.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: August 26, 2003
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Yaffa Beck
  • Patent number: 6361772
    Abstract: A double-stranded cDNA molecule which includes DNA encoding human manganese superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA molecule which encodes human manganese superoxide dismutase has been discovered. Such molecules may be introduced in procaryotic, e.g., bacterial, or eukaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human manganese superoxide dismutase or analogs thereof which may then be recovered. By this invention, human MnSOD gene fragments from various plasmids may be ligated to yield a complete genomic human MnSOD gene fragment. Human MnSOD or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs, or treat inflammations.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: March 26, 2002
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Yaffa Beck
  • Patent number: 5540911
    Abstract: This invention provides plasmids for expression of human superoxide dismutase of analogs thereof. The invention further provides a method of producing enzymatically active human MnSOD or an analog thereof by introducing plasmids for expression of human MnSOD into procaryotic or eucaryotic cells and growing the resulting cells under suitable conditions, including conditions wherein the production medium is supplemented with Mn.sup.++. The invention additionally provides a method of recovering purified enzymatically active MnSOD from procaryotic and eucaryotic cells. Human MnSOD or analogs thereof may be used to reduce reperfusion injury, prolong the survival time of isolated organs or treat inflammations or bronchial pulmonary dysplasia.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: July 30, 1996
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Yaffa Beck
  • Patent number: 5270195
    Abstract: An expression plasmid has been constructed which includes DNA encoding human manganese superoxide dismutase. Such plasmids may be introduced into host cells and the resulting cells cultured or grown under suitable conditions so as to produce enzymatically active human manganese superoxide dismutase or analogs thereof which may then be recovered. A method of producing an enzymatically active analog of human manganese superoxide dismutase by supplementing the culture media with Mn.sup.++ has been developed.
    Type: Grant
    Filed: July 10, 1992
    Date of Patent: December 14, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Yaffa Beck
  • Patent number: 5246847
    Abstract: A double-stranded cDNA molecule which includes DNA encoding human manganese superoxide dismutase has been created. The sequence of one strand of a double-stranded DNA molecule which encodes human maganese superoxide dismutase has been discovered. Such molecules may be introduced in procaryotic, e.g., bacterial, or eukaryotic, e.g., yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions so as to produce human manganese superoxide dismutase or analogs thereof which may then be recovered. Human MnSOD or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs, or treat inflammations.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: September 21, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Yaffa Beck
  • Patent number: 4780414
    Abstract: A novel mutant microorganism Streptococcus zooepidemicus HA-116 ATCC 39920, has been produced. The microorganism produces large amounts of high molecular weight hyaluronic acid. The invention provides a method of obtaining such microorganisms.The invention also concerns a method of obtaining sodium hyaluronate which comprises growing with vigorous agitation a microorganism of the genus Streptococcus under appropriate conditions in a suitable nutrient medium containing a sugar component as a carbon source. The sugar component is present in a substantially constant concentration between 0.2 and 10 grams per liter. The medium has a substantially constant pH between about 6.0 and 7.5 and includes a substantially constant magnesium ion concentration above 0.05 grams per liter. The sodium hyaluronate excreted into the medium by the organism is purified using methods involving precipation, redissolving and reprecipating the hyaluronate.
    Type: Grant
    Filed: January 9, 1986
    Date of Patent: October 25, 1988
    Assignee: Bio-Technology General Corp.
    Inventors: Abraham Nimrod, Benjamin Greenman, Dov Kanner, Moshe Landsberg, Yaffa Beck